Why Aclarion Stock Is Trading Higher Today

Aclarion, Inc. (NASDAQ: ACON) shares are trading higher Monday after the company announced it has executed a strategic partnership agreement solidifying the previously signed Letter of Intent (LOI) with Alphatec Spine, Inc.,

Aclarion, Inc. (NASDAQ:ATEC).

The Details:

The partnership between Aclarion and Alphatec will consist of identifying key opinion leader surgeons to evaluate the Nociscan technology and lead to the co-marketing of Nociscan in targeted markets.

Aclarion shares are racing higher on heavy trading volume following the company's announcement. According to data from Benzinga Pro, more than 15.7 million shares have already been traded in the session, far exceeding the stock's 100-day average volume of less than 174,000 shares.

Aclarion effected a 1-for-16 reverse stock split on Jan. 3, reducing the number of outstanding shares from approximately 13.4 million pre-split shares to approximately 840,000. The stock began trading on a split-adjusted basis at the market open on Jan.4.

Related News: What's Going On With Immunic Stock?

ACON Price Action: According to Benzinga Pro, Aclarion shares are up 64% at $5.02 at the time of publication.

Image: Serhii G. from Pixabay

Total
0
Shares
Related Posts
Read More

This Analyst With 84% Accuracy Rate Sees Around 45% Upside In NVIDIA – Here Are 5 Stock Picks For November From Wall Street’s Most Accurate Analysts

The Dow Jones gained more than 500 points to a new high for the year as investors assessed the recent PCE data. The Dow gained around 8.9% in November, snapping its three-month losing streak, while the S&P 500 gained 8.9% last month.

ADI

Read More

Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting

Seres Therapeutics, Inc. (NASDAQ:MCRB), and Nestlé Health Science today announced the presentation of data from the Phase 3 open-label ECOSPOR IV study evaluating VOWST (fecal microbiota spores,

MCRB